Axon Enterprise, Inc. (NASDAQ:AXON) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $652.73.

AXON has been the topic of several analyst reports. Barclays increased their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. The Goldman Sachs Group increased their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Needham & Company LLC boosted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th.

Axon Enterprise Price Performance

Shares of AXON traded up $13.34 on Friday, hitting $743.63. The company's stock had a trading volume of 1,121,061 shares, compared to its average volume of 732,673. The company has a market capitalization of $57.89 billion, a PE ratio of 192.15, a PEG ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise has a fifty-two week low of $273.52 and a fifty-two week high of $755.05. The company has a 50 day moving average price of $620.57 and a 200 day moving average price of $610.50.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 EPS. On average, research analysts anticipate that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Joshua Isner sold 9,905 shares of the stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $738.03, for a total value of $7,310,187.15. Following the transaction, the president now owns 298,809 shares of the company's stock, valued at approximately $220,530,006.27. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,969 shares of company stock worth $23,127,314 in the last quarter. Corporate insiders own 5.70% of the company's stock.

Hedge Funds Weigh In On Axon Enterprise

A number of large investors have recently modified their holdings of AXON. Capital World Investors boosted its stake in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after buying an additional 841,772 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares during the last quarter. Norges Bank acquired a new stake in Axon Enterprise in the 4th quarter valued at about $482,081,000. GQG Partners LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at about $478,349,000. Finally, GAMMA Investing LLC lifted its stake in Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.